Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Key Points

• Sera Prognostics experienced a significant decline in short interest, dropping by 34.0% from 1,240,000 shares in July to 817,900 shares by August 15th.
• The company's stock closed at $3.34 on Friday, with a market capitalization of $125.82 million and a PE ratio of -3.93.
• Recent earnings showed a loss of ($0.16) EPS, exceeding expectations, but with a negative return on equity of 45.86% and net margin of 30,306.48%.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) saw a significant drop in short interest during the month of August. As of August 15th, there was short interest totaling 817,900 shares, a drop of 34.0% from the July 31st total of 1,240,000 shares. Currently, 3.3% of the shares of the company are sold short. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is presently 2.2 days. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is presently 2.2 days. Currently, 3.3% of the shares of the company are sold short.

Insider Activity

In other news, CEO Zhenya Lindgardt sold 21,158 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the sale, the chief executive officer directly owned 811,136 shares of the company's stock, valued at approximately $2,555,078.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 40,459 shares of company stock valued at $121,485 over the last 90 days. Company insiders own 13.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Wells Fargo & Company MN lifted its stake in Sera Prognostics by 55.2% during the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company's stock worth $107,000 after purchasing an additional 4,691 shares during the period. Barclays PLC lifted its stake in Sera Prognostics by 13.4% during the fourth quarter. Barclays PLC now owns 44,722 shares of the company's stock worth $364,000 after purchasing an additional 5,272 shares during the period. Price T Rowe Associates Inc. MD bought a new position in Sera Prognostics during the fourth quarter worth about $93,000. Northern Trust Corp lifted its stake in Sera Prognostics by 11.8% during the fourth quarter. Northern Trust Corp now owns 272,860 shares of the company's stock worth $2,221,000 after purchasing an additional 28,863 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in Sera Prognostics during the fourth quarter worth about $28,000. Institutional investors own 54.64% of the company's stock.

Sera Prognostics Price Performance

Shares of NASDAQ SERA traded up $0.03 during mid-day trading on Friday, hitting $3.10. The company had a trading volume of 44,671 shares, compared to its average volume of 214,183. The business's 50-day simple moving average is $2.80 and its 200-day simple moving average is $2.87. Sera Prognostics has a 12 month low of $1.37 and a 12 month high of $9.13. The firm has a market cap of $116.78 million, a P/E ratio of -3.65 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. The business had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. As a group, sell-side analysts predict that Sera Prognostics will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.